SWM
ATYR

Spire Wealth Management’s aTyr Pharma ATYR Stock Holding History

Spire Wealth Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-14,000
Closed -$63K – 3009
2021
Q1 		$63K Buy
+14,000
New +$65.8K ﹤0.01% 1614

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Spire Wealth Management's ATYR Position: Q2 2021 in Review

Spire Wealth Management sold out of aTyr Pharma (ATYR) in Q2 2021, closing a stake of 14,000 shares — an estimated $63K sold.

Spire Wealth Management first reported a position in ATYR in Q1 2021 and held it in 1 quarter. The position peaked at $63K in Q1 2021. 29 funds tracked by Wall St. Rank hold ATYR as of Q2 2021.

  • Spire Wealth Management reported no remaining aTyr Pharma position as of Q2 2021 after selling out during the quarter.
  • Spire Wealth Management sold 14,000 aTyr Pharma shares in Q2 2021, an estimated $63K.
  • Spire Wealth Management first reported a position in aTyr Pharma in Q1 2021 and held it in 1 quarter.
  • Spire Wealth Management's aTyr Pharma position peaked at $63K in Q1 2021.
  • 29 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2021.

Based on Spire Wealth Management's 13F filing for Q2 2021, filed 26 Jul 2021.